Streetbeat News

Regulatory

MRTX

Mirati Therapeutics, Inc. (NASDAQ:MRTX) announced a presentation of two-year follow-up from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. The findings will be presented at the 2023 World Conference on Lung Cancer.

Portfolio Pulse from Happy Mohamed

August 21, 2023 | 8:00 pm

INPX

Inpixon has received a Notice of Allowance for its U.S. patent application 14/556,034 titled 'Proactive Loss Prevention System'. This system is designed for protecting assets in any venue and retail spaces using wireless-based technology.

Portfolio Pulse from Happy Mohamed

August 21, 2023 | 7:58 pm

ETHUSD

Ethereum co-founder, Vitalik Buterin, has been awarded Taiwan's Employment Gold Card, a recognition of his contributions to the digital and crypto realms. This allows him to travel in and out of Taiwan with ease for the next three years. The award highlights Taiwan's recognition of global tech leaders and its commitment to fostering a digital environment. Buterin's acknowledgment of the strong Ethereum community in Taiwan underscores the nation's growing prominence in the global crypto landscape.

Portfolio Pulse from Murtuza Merchant

August 21, 2023 | 7:30 pm

WE

Trading of WeWork shares has been temporarily halted due to pending news.

Portfolio Pulse from Happy Mohamed

August 21, 2023 | 7:25 pm

FLO

Flowers Foods Inc has filed for a mixed shelf offering with the SEC, though the size of the offering has not been disclosed.

Portfolio Pulse from Happy Mohamed

August 21, 2023 | 7:24 pm

REGN

RHHBY

The FDA has approved Regeneron Pharmaceuticals' Eylea HD Injection 8 mg for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. This approval is seen as a shield against potential biosimilar competition. Truist Securities and BMO Capital remain bullish on Regeneron due to this approval. However, Regeneron is still involved in a lawsuit with Viatris regarding the potential introduction of their Eylea biosimilar. RBC Capital Markets has increased the price target for Regeneron from $820 to $830.

Portfolio Pulse from Vandana Singh

August 21, 2023 | 7:04 pm

EXEL

IPSEY

RHHBY

Exelixis Inc, Roche Holdings AG, and Ipsen announced that their Phase 3 CONTACT-02 pivotal trial evaluating Cabometyx in combination with Tecentriq has met one of the primary endpoints, showing a significant improvement in progression-free survival. The trial is for patients with metastatic castration-resistant prostate cancer. The estimated total U.S. market value is approximately $1.9 billion. Analysts from William Blair maintain the Outperform rating on Exelixis' stock.

Portfolio Pulse from Vandana Singh

August 21, 2023 | 6:57 pm

SPY

The U.S. National Highway Traffic Safety Administration (NHTSA) has proposed a rule that would require automakers to install a system in new vehicles to remind passengers to buckle their seat belts, including those in the rear seats. This proposal could potentially increase costs for automakers.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 6:34 pm

NBIX

TEVA

The FDA has approved Neurocrine Biosciences' Ingrezza for the treatment of adults with chorea associated with Huntington's disease. The approval is supported by data from two clinical studies. Analysts from William Blair anticipate a gradual introduction of Ingrezza to the patient group, with 2024 marked as a major growth year. HC Wainwright raised the price target for Neurocrine Biosciences from $140 to $146.

Portfolio Pulse from Vandana Singh

August 21, 2023 | 6:24 pm

DWAC

The merger between Trump Media & Technology Group (TMTG) and Digital World Acquisition Corporation (DWAC) has faced several setbacks and regulatory pressure since its announcement in October 2021. The merger approval vote has been pushed back to Dec. 31, 2023. DWAC faces a deadline of Sept. 8, 2023, to obtain shareholder approval to extend the merger to September 2024 or it faces liquidation. DWAC stock has been highly volatile in 2023, with several spikes around Trump's four indictments.

Portfolio Pulse from Chris Katje

August 21, 2023 | 6:22 pm